Postchemotherapy residual masses in advanced seminoma: Current management and outcomes

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 869-874

  Quek, Marcus L ^a   Simma Chiang, Vannita ^b   Stein, John P ^b   Pinski, Jacek ^b   Quinn, David I ^b   Skinner, Donald G ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cisplatin; Retroperitoneum; Seminoma; Testicular neoplasms; Testis

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GALLIUM; IFOSFAMIDE; VINBLASTINE;

ADVANCED CANCER; ALGORITHM; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLINICAL PROTOCOL; DIAGNOSTIC IMAGING; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; NON INVASIVE MEASUREMENT; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; RADIOSENSITIVITY; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SEMINOMA; SURGICAL TECHNIQUE; TUMOR VOLUME;

ALGORITHMS; HUMANS; MALE; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; RETROPERITONEAL NEOPLASMS; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; SURVIVAL; TESTICULAR NEOPLASMS;

EID: 27744481919     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.869     Document Type: Review

References (41)

1. Steele GS, Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology 11, 717-737 (1997).
2. Gospodarwicz MK, Sturgeon JF, Jewett MA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin. Oncol. 25, 160-173 (1998).
3. Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J. Clin. Oncol. 17, 1146 (1999).
4. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89, 1429-1439 (1997).
5. Loehrer PJ Sr, Birch R, Williams SD et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J. Clin. Oncol. 5, 1212-1220 (1987).
6. Loehrer PJ Sr, Williams SD, Einhorn LH. Status of chemotherapy for testis cancer. Urol. Clin. North Am. 14, 713-720 (1987).
7. Herr HW, Sheinfeld J, Puc HS et al. Surgery for a post-chemotherapy residual mass in seminoma. J. Urol. 157, 860-862 (1997).
8. Friedman EL, Garnick MB, Stomper PC et al. Therapeutic guidelines and results in advanced seminoma. J. Clin. Oncol. 3, 1325-1332 (1985).
9. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br. J. Cancer 52, 7-13 (1985).
10. Horwich A, Dearnaley DP, Duchesne GM et al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J. Clin. Oncol. 7, 1150-1156 (1989).
11. Flechon A, Bompas E, Biton P et al. Management of post-chemotherapy residual masses in advanced seminoma. J. Urol. 168, 1975-1979 (2002).
12. Stomper PC, Jochelson MS. Friedman EL, Garnick MB, Richie JP. CT evaluation of advanced seminoma treated with chemotherapy. AJR Am. J. Roentgenol 146, 745-748 (1986).
13. Schultz SM, Einhorn LH, Conces DJ Jr. et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J. Clin. Oncol. 7, 1497-1503 (1989).
14. Vuky J, Tickoo SK, Sheinfeld J et al. Salvage chemotherapy for patients with advanced pure seminoma. J. Clin. Oncol. 20, 297-301 (2002).
15. Horwich A, Paluchowska B, Norman A et al. Residual mass following chemotherapy of seminoma. Ann. Oncol. 8, 37-40 (1997).
16. Fossa SD, Kullmann G, Lien HH et al. Chemotherapy of advanced seminoma: clinical significance of radiological findings before and after treatment. Br. J. Urol. 64, 530-534 (1989).
17. Fossa SD, Droz JP, Stoter G et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br. J. Cancer 71, 619-624 (1995).
18. Ellison MF, Mostofi FK, Flanigan RC. Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J. Urol. 140, 618-620 (1988).
19. Mosharafa AA, Foster RS, Leibovich BC et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J. Urol. 169, 2126-2128 (2003).
20. Kelly R, Skinner D, Yellin AE et al. En bloc aortic resection for bulky metastatic germ cell tumors. J. Urol. 153, 1849-1851 (1995).
21. Spitz A, Wilson TG, Kawachi MH et al. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J. Urol. 158, 1813-1818 (1997).
22. Herr HW, Bosl G. Residual mass after chemotherapy for seminoma: changing concepts of management. J. Urol. 137, 1234-1235 (1987).
23. Motzer R, Bosl G, Heelan R et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J. Clin. Oncol. 5, 1064-1070 (1987).
24. Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J. Clin. Oncol. 14, 454-460 (1996).
25. Ravi R, Ong J, Oliver RT et al. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int. 83, 649-653 (1999).
26. Hofmockel G, Gross A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol. Int. 57, 38-42 (1996).
27. Kamat MR, Kulkarni JN, Tongaonkar HB et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma J. Surg. Oncol. 51, 65-67 (1992).
28. Marks LB, Anscher MS, Shipley WU. The role of radiation therapy in the treatment of testicular germ cell tumors. Hematol. Oncol. Clin. North Am. 5, 1143-1172 (1991).
29. Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC Testicular Tumour Working Party. Eur. J. Cancer 33, 829-835 (1997).
30. Ravi R, Vasanthan A. Intraoperative irradiation: another option for the treatment of > or = 3 cm residual mass following chemotherapy for advanced testicular seminoma. Urol. Int. 55, 137-140 (1995).
31. Miller KD, Loehrer PJ, Gonin R et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J. Clin. Oncol. 15, 1427-1431 (1997).
32. Warren GP, Einhorn LH. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J. Clin. Oncol. 13, 2784-2788 (1995).
33. Ganjoo KN, Chan RJ, Sharma M et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J. Clin. Oncol. 17, 3457-3460 (1999).
34. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 22, 1034-1039 (2004).
35. De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Oncol. 19, 3740-3744 (2001).
36. Becherer A, De Santis M, Karanikas G et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur. J. Radiol. 54, 284-288 (2005).
37. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol. 15, 2559-2563 (1997).
38. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 18, 2413-2418 (2000).
39. Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J. Clin. Oncol. 20, 1859-1863 (2002).
40. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 20, 2031-2037 (2002).
41. Bokemeyer C, Kollmannsberger C, Stenning S et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br. J. Cancer 91, 683-687 (2004).